NCT00923572
Completed
Not Applicable
Yasmin Regulatory Post Marketing Surveillance
ConditionsContraception
InterventionsEE30/DRSP (Yasmin, BAY86-5131)
Overview
- Phase
- Not Applicable
- Intervention
- EE30/DRSP (Yasmin, BAY86-5131)
- Conditions
- Contraception
- Sponsor
- Bayer
- Enrollment
- 777
- Primary Endpoint
- Safety and efficacy in real practice
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women who need oral contraceptive
Exclusion Criteria
- •Patient who belongs to contraindication listed on the product label.
Arms & Interventions
Group 1
Intervention: EE30/DRSP (Yasmin, BAY86-5131)
Outcomes
Primary Outcomes
Safety and efficacy in real practice
Time Frame: After 6 cycle of treatment
Secondary Outcomes
- Medical History(At initial visit)
- Demography(At initial visit)
- Administration period of Yasmin(After 6 cycle of treatment or at the point of withdrawan)
- Adverse Event / Serious AE collection(At point of the occurence)
- Patient's compliance(After 6 cycle of treatment or at the point of withdrawan)
Similar Trials
Completed
Not Applicable
Regulatory Post Marketing Surveillance Study on YAZContraceptionPremenstrual SyndromeAcneNCT00998257Bayer770
Completed
Not Applicable
Primovist Regulatory Post Marketing Surveillance (PMS)LiverNCT00924248Bayer4,358
Completed
Not Applicable
Angeliq Regulatory Post Marketing SurveillancePostmenopausal PeriodOsteoporosis, PostmenopausalNCT01064453Bayer4,078
Completed
Not Applicable
Eylea Post Marketing Surveillance(PMS)Macular DegenerationNCT01783925Bayer3,206
Recruiting
Not Applicable
Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea PatientsHyperphosphatemiaNCT06186934Kyowa Kirin Korea Co., Ltd.600